Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 17, 2020
Daily News
July 17, 2020
- Japan Might Tap Coronavirus Emergency Reserve for Vaccines
July 17, 2020
- Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
- JPMA Reiterates It’s Not the Right Time for Off-Year Drug Price Survey
July 17, 2020
- Mitsubishi Tanabe Earns Indonesian OK for ALS Med
July 17, 2020
- Kyowa Pharma Expanding Focus Beyond Drugs, Eyes New Diagnostic/Treatment Options in CNS
July 17, 2020
- Number of Contract Sales Reps Up 10.8% to 3,445, with New Drug Launches
July 17, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…